RefleXion Wins 2022 Pantheon Award from California Life Sciences
November 7, 2022
19th Annual Pantheon Awards celebrate excellence in California’s life sciences sector
HAYWARD, Calif., Nov. 4, 2022 – RefleXion Medical, a therapeutic oncology company pioneering SCINTIX™ biology-guided radiotherapy*, a new modality for treating all stages of cancer, announced today that California Life Sciences (CLS), the state’s largest and most influential life sciences organization, has awarded it the 2022 Pantheon Award for Convergent Technologies. The award recognizes RefleXion for its breakthrough technology that transforms radiotracers from diagnostic agents to biological guides to direct external-beam radiotherapy delivery in real time with the aim of treating patients with any stage of solid tumor cancers.
We are grateful to CLS for recognizing our novel SCINTIX biology-guided radiotherapy with the 2022 Pantheon Award for Convergent Technology
CEO and President of RefleXion
“We are grateful to CLS for recognizing our novel SCINTIX biology-guided radiotherapy with the 2022 Pantheon Award for Convergent Technology,” said Todd Powell, CEO and president of RefleXion. “Over 10 years ago, we set out to fulfill a big dream – that of converging technology from radiation oncology with radiopharmaceuticals to scale radiotherapy to multiple tumors so that it could be used to treat patients with late-stage cancer. When used in combination with drug therapies, we believe SCINTIX will amplify those treatments to improve outcomes for patients with all stages of solid tumor cancers.”
Pantheon, now in its 19th year, is a long-standing awards celebration that brings together more than 500 industry pioneers to recognize the contributions of leading life sciences innovators in the state. Winners were announced at the awards ceremony on Thu., Nov. 3 in San Francisco.
“Pantheon Award winners represent California’s brightest innovators, entrepreneurs, and scientists, and we champion their progress in delivering innovative solutions for healthier lives,” said Mike Guerra, CLS president and CEO. “CLS congratulates RefleXion on their deserved recognition, and we look forward to seeing their work continue to make an impact.”
Visit www.califesciences.org/pantheon to learn more about the Pantheon Awards.
About RefleXion Medical
RefleXion is a privately-held therapeutic oncology company developing SCINTIX biology-guided radiotherapy, which brings the potential to move beyond single tumor therapy to one day treating multiple metastatic tumors throughout the body in the same treatment session. SCINTIX radiotherapy incorporates positron-emission tomography (PET) data to enable tumors to continuously signal their location. SCINTIX technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency. The RefleXion® X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).
*SCINTIX™ biology-guided radiotherapy is limited by U.S. law to investigational use.